Method, device, and kit for maintaining physiological levels of steroid hormone in a subject

• US 20100022494A1
• Filed: 07/24/2008
• Published: 01/28/2010
• Est. Priority Date: 07/24/2008
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Ishikawa, Muriel Y., Wood, Lowell L. JR., Rivet, Dennis J., Hyde, Roderick A., Sweeney, Elizabeth A., Wood, Victoria Y.H.
• Application Number:
  US12/220,704
• Publication Number:
  US 20100022494A1
• Time in Patent Office: Days
• US Class Current: 514/178
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system

Abstract

A method, device, or kit is provided which maintain a substantially physiological level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on steroid hormone levels prior to disease diagnosis in the subject and on current steroid hormone levels in the subject, wherein the at least one treatment regimen is configured to maintain the subject'"'"'s one or more steroid hormones or metabolites or modulators thereof at substantially physiological pre-disease levels. The method, device, or kit can be used for the treatment of a disease or condition in the mammalian subject.

Claims

1. A method for maintaining a substantially physiological level of one or more steroid hormones in a mammalian subject in need thereof comprising:

providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on steroid hormone levels prior to disease diagnosis in the subject and on current steroid hormone levels in the subject.

2. The method of claim 1, wherein the at least one treatment regimen is configured to maintain the subject'"'"'s one or more steroid hormones or metabolites or modulators thereof at substantially physiological pre-disease levels.

3. The method of claim 1, wherein the current cyclic steroid hormone levels are based on steroid hormone levels during a period of disease in the subject.

4. The method of claim 1, further comprising determining the one or more steroid hormones levels in the subject during a treatment period.

5. The method of claim 4, wherein the treatment period includes a time period preceding treatment or a time period during treatment with the at least one treatment regimen.

6. The method of claim 4, wherein the determining the one or more steroid hormones levels occurs at multiple time points during the treatment period.

7. The method of claim 4, further comprising providing to the subject at least one second treatment regimen adjusted to maintain the subject'"'"'s one or more steroid hormones or one or more metabolites or modulators thereof at substantially physiological levels.

8. The method of claim 1, wherein the at least one treatment regimen is determined based at least in part on a time-history of serum steroid hormone levels in the subject, on inferred peak values or minimal values of serum steroid hormone levels in the subject, on age of the subject, or on categorization relative to profiles of patient populations.

9. The method of claim 1, wherein the at least one treatment regimen is determined based at least in part on Fourier analysis of the cyclic steroid hormone levels in the subject, or on harmonic analysis of the cyclic steroid hormone levels in the subject.

10. The method of claim 1, wherein the at least one treatment regimen is determined based on a genetic profile of the subject.

11. The method of claim 1, further comprising determining a genetic profile of the subject.

12. The method of claim 1, wherein the at least one treatment regimen is determined based at least in part on scaled values of the steroid hormone levels prior to the disease diagnosis in the subject.

13. The method of claim 12, wherein the at least one treatment regimen is determined based at least in part on the scaled value approximately equal to one.

14. The method of claim 12, wherein the at least one treatment regimen is determined based at least in part on the scaled value dependent on age of the subject.

15. The method of claim 1, wherein the subject has neoplastic disease.

16. The method of claim 15, wherein the neoplastic disease includes at least one of breast cancer, uterine cancer, uterine sarcoma, endometrial carcinoma, ovarian cancer, prostate cancer, or testicular cancer.

17. The method of claim 1, wherein the subject has lost ovarian function or testicular function resulting from surgery or disease.

18. The method of claim 1, wherein the subject has a neurological disease.

19. The method of claim 18, wherein the neurological disease is Alzheimer'"'"'s disease.

20. The method of claim 1, wherein the subject has a metabolic disease.

21. The method of claim 20, wherein the metabolic disease includes at least one of diabetes, metabolic syndrome, or thyroid disease.

22. The method of claim 1, further comprising determining the subject'"'"'s one or more steroid hormones levels when the subject is healthy and has no underlying condition affecting production of steroid hormones.

23. The method of claim 1, wherein the at least one treatment regimen is determined while the subject has an underlying condition affecting production of hormones.

24. The method of claim 1, wherein the subject is female.

25. The method of claim 24, wherein the at least one treatment regimen is determined based on steroid hormone when the subject is premenopausal, and the current steroid hormone levels are determined when the subject is peri-menopausal, early menopausal, late menopausal, or post menopausal.

26. The method of claim 1, wherein the subject is male.

52. The method of claim 5l, wherein the one or more ratios include a ratio of different estradiols, an estradiol to an estrone, or a testosterone to an estrogen.

27. A method for restoring a physiological level of one or more steroid hormones in a mammalian subject comprising:

providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on steroid hormone levels prior to disease diagnosis in the subject and on current steroid hormone levels in the subject.

28. The method of claim 27, wherein the at least one treatment regimen is configured to maintain the subject'"'"'s one or more steroid hormones or metabolites or modulators thereof at substantially physiological pre-disease levels.

29. The method of claim 27, wherein the subject is female.

30. The method of claim 27, wherein the subject is male.

31. The method of claim 27, further comprising determining the one or more steroid hormones levels in the subject during a treatment period.

32. The method of claim 31, wherein the treatment period includes a time period preceding treatment or a time period during treatment with the at least one treatment regimen.

33. The method of claim 31, wherein the determining the one or more steroid hormones levels occurs at multiple time points during the treatment period.

34. The method of claim 31, further comprising providing to the subject at least one second treatment regimen adjusted to maintain the subject'"'"'s one or more steroid hormones or one or more metabolites or modulators thereof at substantially physiological pre-disease levels.

35. The method of claim 27, wherein the at least one treatment regimen is determined based at least in part on a time-history of serum steroid hormone levels in the subject, on inferred peak values or minimal values of serum steroid hormone levels in the subject, on age of the subject, or on categorization relative to profiles of patient populations.

36. The method of claim 27, wherein the at least one treatment regimen is determined based at least in part on Fourier analysis of the cyclic steroid hormone levels in the subject, or on harmonic analysis of the pre-disease steroid hormone levels in the subject.

37. The method of claim 27, wherein the at least one treatment regimen is determined based on a genetic profile of the subject.

38. The method of claim 27, wherein the at least one treatment regimen is determined based at least in part on scaled values of the pre-disease steroid hormone levels in the subject.

39. The method of claim 38, wherein the at least one treatment regimen is determined based at least in part on a scaled value approximately equal to one.

40. The method of claim 38, wherein the at least one treatment regimen is determined based at least in part on a scaled value dependent on age of the subject.

41. The method of claim 27, further comprising determining the one or more steroid hormones levels in the subject when the subject is pre-disease and has no underlying condition affecting production of steroid hormones.

42. The method of claim 41, wherein the at least one treatment regimen is determined based on a previous time-history of serum steroid hormone levels in the subject, or on inferred peak values or minimal values of serum steroid hormone levels in the subject.

43. The method of claim 41, wherein the at least one treatment regimen is determined based on a genetic profile of the subject.

44. The method of claim 27, wherein the at least one treatment regimen is determined while the subject has an underlying condition affecting production of hormones.

45. The method of claim 44, wherein the subject has undergone oopherectomy, and the at least one treatment regimen is determined based on pre-surgical cyclic steroid hormone levels in the subject.

48. The method of claim 27, wherein the hormones or their metabolically related compounds are sterols, androgens, progestogens, estrogens, follicle-stimulating hormone, luteinizing hormone, inhibin B, anti-Mullerian hormone thyroid-related hormones, or analogs or derivatives thereof.

49. The method of claim 48, wherein the androgen is testosterone.

50. The method of claim 48, wherein the estrogen is an estradiol or estrone.

51. The method of claim 27, wherein the at least one treatment regimen is determined based at least in part on one or more ratios of levels of the steroid hormones or metabolites or modulators thereof in the subject, and the treatment regimen restores the one or more ratios to physiological pre-disease levels.

53. The method of claim 51, wherein the one or more ratios include a ratio of the one or more steroid hormones or metabolically related compounds at different time intervals of a pre-disease period in the subject.

54. The method of claim 27, wherein the at least one treatment regimen is determined based on the subject'"'"'s pre-disease levels of one or more steroid hormone receptors and on the subject'"'"'s current levels of the one or more steroid hormone receptors.

55. The method of claim 54, wherein the one or more hormone receptors is an estrogen receptor.

56. The method of claim 27, wherein the at least one treatment regimen is based on diagnostic data.

61. The method of claim 27, wherein the at least one treatment regimen is determined using an algorithm designed to determine a dosage of the one or more steroid hormones or metabolites, modulators, or analogs thereof in the at least one treatment regimen.

62. The method of claim 27, wherein the subject'"'"'s pre-disease steroid hormone levels-are determined for a period of time from approximately one week to approximately one year.

46-47. -47. (canceled)

57-60. -60. (canceled)

63-74. -74. (canceled)

75. A kit comprising

at least one treatment regimen including one or more steroid hormones or metabolites, modulators, or analogs thereof providing varying dosages of the one or more steroid hormones or metabolites, modulators, or analogs thereof, the at least one treatment regimen based on steroid hormone levels prior to disease diagnosis in a subject and on current cyclic steroid hormone levels in the subject, and

instructions for administering the at least one treatment regimen and for monitoring the effectiveness of hormone replacement therapy in the subject.

76-81. -81. (canceled)